ABUS
Price
$1.93
Change
-$0.06 (-3.02%)
Updated
Sep 22, 6:59 PM EST
44 days until earnings call
INO
Price
$0.39
Change
-$0.00 (-0.00%)
Updated
Sep 22, 6:59 PM EST
43 days until earnings call

Compare trend and price ABUS vs INO

Header iconABUS vs INO Comparison
Open Charts ABUS vs INOBanner chart's image
Arbutus Biopharma
Price$1.93
Change-$0.06 (-3.02%)
Volume$673.28K
CapitalizationN/A
Inovio Pharmaceuticals
Price$0.39
Change-$0.00 (-0.00%)
Volume$1.96M
CapitalizationN/A
View a ticker or compare two or three
ABUS vs INO Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ABUS vs. INO commentary
Sep 25, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and INO is a StrongSell.

COMPARISON
Comparison
Sep 25, 2023
Stock price -- (ABUS: $1.93 vs. INO: $0.39)
Brand notoriety: ABUS: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 186% vs. INO: 118%
Market capitalization -- ABUS: $323.38M vs. INO: $105.57M
ABUS [@Biotechnology] is valued at $323.38M. INO’s [@Biotechnology] market capitalization is $105.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $410.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABUS and INO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 3 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 3 bullish, 6 bearish.
  • INO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, INO is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а -5.39% price change this week, while INO (@Biotechnology) price change was -1.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.79%. For the same industry, the average monthly price growth was +32.38%, and the average quarterly price growth was +31.88%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 08, 2023.

INO is expected to report earnings on Nov 07, 2023.

Industries' Descriptions

@Biotechnology (-4.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ABUS with price predictions.
OPEN
A.I.dvisor published
a Summary for INO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ABUS($323M) has a higher market cap than INO($106M). ABUS YTD gains are higher at: -17.167 vs. INO (-74.756). ABUS has higher annual earnings (EBITDA): -70.5M vs. INO (-162.17M). INO has more cash in the bank: 195M vs. ABUS (152M). ABUS has less debt than INO: ABUS (2.04M) vs INO (30.8M). ABUS has higher revenues than INO: ABUS (23.5M) vs INO (9.62M).
ABUSINOABUS / INO
Capitalization323M106M305%
EBITDA-70.5M-162.17M43%
Gain YTD-17.167-74.75623%
P/E RatioN/AN/A-
Revenue23.5M9.62M244%
Total Cash152M195M78%
Total Debt2.04M30.8M7%
FUNDAMENTALS RATINGS
ABUS vs INO: Fundamental Ratings
ABUS
INO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
8290
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (23) in the Medical Specialties industry is in the same range as ABUS (45) in the Biotechnology industry. This means that INO’s stock grew similarly to ABUS’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ABUS (100) in the Biotechnology industry. This means that INO’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's SMR Rating (96) in the Biotechnology industry is in the same range as INO (97) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's Price Growth Rating (82) in the Biotechnology industry is in the same range as INO (90) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSINO
RSI
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 5 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 7 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
83%
Aroon
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
82%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PEMBX10.550.07
+0.67%
Putnam Emerging Markets Equity B
SVXAX51.720.02
+0.04%
Smead International Value A
MXKWX8.40-0.01
-0.12%
Empower S&P 500® Index Institutional
NGRIX8.89-0.04
-0.49%
Neuberger Berman Global Real Est I
BIOIX32.35-0.22
-0.68%
Baron Opportunity Instl

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with MDGL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-3.02%
MDGL - ABUS
48%
Loosely correlated
-3.87%
ICPT - ABUS
45%
Loosely correlated
-2.96%
ARRY - ABUS
43%
Loosely correlated
-4.72%
AXON - ABUS
42%
Loosely correlated
-0.36%
ORMP - ABUS
42%
Loosely correlated
-1.14%
More

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with IMGN. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then IMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+1.86%
IMGN - INO
61%
Loosely correlated
-1.07%
MDGL - INO
56%
Loosely correlated
-3.87%
NTLA - INO
55%
Loosely correlated
-3.40%
CRSP - INO
54%
Loosely correlated
-1.24%
AXON - INO
53%
Loosely correlated
-0.36%
More